Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

New data from the IRAKLIA and IZALCO trials, presented at the 2025 ASCO Annual Meeting, demonstrate that subcutaneous ...

The Ministry of Health is partnering with Sanofi to boost immunisation drives and public awareness from 2025-2027.

Sublime’s award is just one of the 24 that were rolled back after U.S. Secretary of Energy Chris Wright announced the awards ...

Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...

The investment includes a significant boost to research and development and the expansion of partnerships with domestic ...